Hypothesis

Microbial conversion of oral resveratrol to dihydroresveratrol (DHR) and lunularin (LUN) in the colon generates circulating metabolites that cross the blood‑brain barrier, activate neuronal SIRT1, and reset central NAD+/NADH redox balance through vagal afferent feedback, thereby driving longevity benefits independently of parent resveratrol action in the brain.

Mechanistic Rationale

Oral resveratrol is extensively metabolized by gut microbiota, yielding DHR and LUN that reach systemic concentrations far exceeding the parent compound [1]. These reduced polyphenols retain phenolic rings but possess altered hydrophilicity, enabling passive diffusion or carrier‑mediated transport across the blood‑brain barrier [4]. Once in the CNS, DHR/LUN can bind SIRT1’s allosteric site with higher affinity than resveratrol because their reduced C‑C double bond stabilizes the enzyme‑activator complex, a prediction supported by improved cellular SIRT1 activation of membrane‑permeable derivatives [4]. SIRT1 activation raises neuronal NAD+ levels by deacetylating and activating NAMPT, shifting the NAD+/NADH ratio toward oxidation [5]. An elevated neuronal NAD+ state enhances mitochondrial oxidative phosphorylation and activates downstream FOXO and PGC‑1α pathways, promoting stress resistance and neurogenesis.

Importantly, neuronal SIRT1 activation modulates autonomic output via the hypothalamus, increasing vagal efferent tone. Heightened vagal signaling feeds back to the gut, reinforcing a microbiota composition that favors continued DHR/LUN production—a positive feedback loop. Thus, the gut‑brain axis operates bottom‑up: microbial metabolites set the brain’s redox baseline, which in turn shapes gut function through vagal pathways.

Testable Predictions

1. Colon‑targeted delivery of DHR/LUN (e.g., pH‑dependent nanoparticles) will increase brain SIRT1 activity and NAD+/NADH ratio more effectively than equivalent oral resveratrol doses, whereas intracranial injection of resveratrol will not replicate these effects.
2. Selective vagal afferent blockade (using perivagal capsaicin or chemogenetic silencing) will abolish the NAD+‑raising and SIRT1‑activating effects of colon‑targeted DHR/LUN, despite unchanged metabolite levels in plasma.
3. Fecal microbiota transplantation from resveratrol‑treated donors into germ‑deficient mice will confer elevated brain NAD+/NADH and SIRT1 activity only when the recipient’s vagal afferents are intact.
4. Mice lacking neuronal SIRT1 (Syn‑Cre SIRT1^fl/fl) will show no improvement in neurocognitive aging markers after colon‑targeted DHR/LUN treatment, confirming the metabolite‑SIRT1 axis.

Experimental Approach

• Formulate DHR and LUN into enteric‑coated PLGA nanoparticles that release in the distal colon; confirm release profile in vitro.
• Treat aged mice with (i) free resveratrol, (ii) colon‑targeted DHR/LUN nanoparticles, (iii) vehicle, for 12 weeks.
• Measure brain SIRT1 activity (fluorometric deacetylase assay), NAD+/NADH ratios (LC‑MS), and downstream markers (acetyl‑p53, PGC‑1α expression) in hippocampus and cortex.
• Simultaneously record vagal afferent firing (in vivo electrophysiology) and gut microbiota composition (16S rRNA sequencing).
• Apply chemogenetic inhibition of vagal afferents (hM4Di DREADDs) in a subset to test necessity of the neural arm.
• Perform fecal transplants from donor groups into antibiotic‑treated recipients, with or without vagal blockade, to assess transfer of the NAD+ phenotype.
• End‑point behavioral assays (Morris water maze, novel object recognition) to link molecular changes to cognitive outcomes.

Falsifiability

If colon‑targeted DHR/LUN fails to raise brain SIRT1 activity or NAD+/NADH compared with free resveratrol, or if vagal blockade does not diminish these central effects, the hypothesis is refuted. Likewise, if fecal transplants transfer the phenotype independent of vagal integrity, the bottom‑up model would be untenable.